Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.70EUR
22 Feb 2018
Change (% chg)

€-0.00 (-0.18%)
Prev Close
€1.70
Open
€1.72
Day's High
€1.72
Day's Low
€1.67
Volume
397,415
Avg. Vol
1,361,479
52-wk High
€4.26
52-wk Low
€1.45

Latest Key Developments (Source: Significant Developments)

Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - PHARMA MAR SA ::CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT.  Full Article

Pharma Mar Requests Re-Examination Process For Aplidin From EMA
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - PHARMA MAR SA ::REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA).AFTER FINALIZING RE-EXAMINATION PROCESS, EUROPEAN COMMISSION TO ISSUE FINAL VERDICT ON THE MARKETING AUTHORIZATION APPLICATION (MAA) FOR APLIDIN AROUND JUNE OR JULY.  Full Article

Pharma Mar Signs Distribution License Agreement For Aplidin In Israel
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - PHARMA MAR SA ::SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL.  Full Article

Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment
Friday, 15 Dec 2017 

Dec 15 (Reuters) - PHARMA MAR SA ::THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA.AFTER OPINION OF CHMP, EUROPEAN COMMISSION TO ISSUE FINAL DECISION, EXPECTED IN MARCH OR APRIL, 2018.  Full Article

Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - PHARMA MAR SA ::PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE).  Full Article

Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
Monday, 13 Nov 2017 

Nov 13 (Reuters) - PHARMA MAR SA ::PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA.OBSERVED DISEASE CONTROL RATE AT 60 PERCENT, INCLUDING PARTIAL RESPONSES IN 12 PERCENT AND STABILIZATION IN 48 PERCENT OF CASES.‍​.  Full Article

Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - PHARMA MAR SA ::SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY.FORMAL WRITTEN DECISION FROM EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) IS EXPECTED FOLLOWING ITS DECEMBER 2017 MEETING (DEC 11 TO DEC 15).COMPANY DEEPLY SURPRISED ABOUT CHMP NEGATIVE TREND VOTE GIVEN RESULTS OF PHASE III TRIAL.CHMP NEGATIVE TREND VOTE WAS VERBALLY COMMUNICATED TO COMPANY BY EMA.  Full Article

Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - PHARMA MAR SA ::SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA.TO RECEIVE A NON-DISCLOSED UPFRONT PAYMENT AND TO BE ELIGIBLE FOR ADDITIONAL REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES MILESTONES.TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SELL THE PRODUCT TO BORYUNG PHARM FOR COMMERCIAL USE.ZEPSYRE IS CURRENTLY IN LATE-STAGE CLINICAL DEVELOPMENT FOR PLATINUM-RESISTANT OVARIAN CANCER AND FOR SMALL-CELL LUNG CANCER.  Full Article

Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - PHARMA MAR SA ::9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO.9-MONTH NET LOSS 14.5 MILLION EUROS VERSUS LOSS 16.6 MILLION EUROS YEAR AGO.9-MONTH NEGATIVE EBITDA 4.6 MILLION EUROS VERSUS NEGATIVE 5.6 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar reports positive results from phase II trial with PM1183 in breast cancer
Monday, 10 Oct 2016 

Pharma Mar SA : Reports positive results from phase II trial with lurbinectedin (PM1183) in patients with metastatic breast cancer .The study met the initial objective for an overall response rate (ORR) in 41 percent of patients.  Full Article

BRIEF-Pharma Mar Announces Positive Results Of Its MI13004 Antibody Conjugate

* ANNOUNCES POSITIVE RESULTS OF ITS ANTIBODY CONJUGATE ACTIVE IN BREAST, OVARIAN AND GASTRIC CANCERS Source text for Eikon: